PreludeDx Announces Preferred Vendor Agreement with Galaxy Health Network for its New DCIS Test, DCISionRT – InsuranceNewsNet
Galaxy agreement provides access to more than 3.5 million patients Through a network of more than 400,000 suppliers
“Galaxy joins the growing list of health insurance providers that cover DCISionRT, enabling even more physicians and patients to access DCISionRT whether or not they are on the network,” said
About Galaxy Health Network
Galaxy Health Network, headquartered in Arlington,
About DCISionRT for Breast DCIS
DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts the benefit of radiation therapy. Patients with DCIS have cancer cells lining the milk ducts of the breast, but they have not spread to surrounding breast tissue. In the United States, more than 60,000 women are newly diagnosed with DCIS each year. DCISionRT, developed by PreludeDx on technology licensed from
PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from
For more information about how PreludeDx is making a difference for patients, please visit the company’s website: https://preludedx.com and follow us on Twitter @PreludeDx, Facebook, Instagram and LinkedIn.
PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, Decision Score, The DCIS Test, Know Your Risk and Your Biology, Your Decision are registered trademarks of
View original content to download multimedia: https://www.prnewswire.com/news-releases/preludedx-announces-preferred-provider-agreement-with-galaxy-health-network-for-its-novel-dcis-test -decisionrt-301615267.html
Comments are closed.